Report accuses Covid vaccine makers of putting profits before lives
Only 0.3% of the 5.76 billion doses administered worldwide have been distributed to low-income countries
In a new report commissioned by Amnesty International, six pharma companies heading the global roll-out of Covid-19 vaccines have been criticised for refusing to waive intellectual property rights and share vaccine technology.
Amnesty International has said that such refusal, along with failing to prioritise vaccine deliveries to poorer countries, is "fuelling an unprecedented human rights crisis".
The report A Double Dose of Inequality: Pharma companies and the Covid-19 vaccines crisis, assessed AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax and Pfizer and concluded that the industry is "woefully failing to respect human rights".
In a statement, Agnès Callamard, Amnesty International’s Secretary General, said that Big Pharma's intentional blocking of knowledge transfer, along with their "wheeling and dealing in favour of wealthy states" has created a "predictable" and "devastating" vaccine scarcity for others.
By the end of 2022, BioNTech, Moderna and Pfizer combined are set to make a $130 billion – a fact which serves to underscore their putting profits before lives, said Agnès Callamard.
The report also revealed that out of 5.76 billion doses administered worldwide, only 0.3% have been distributed to low-income countries. Furthermore, some of the assessed companies have continued to stock up vaccine supplies for states known to be hoarding the vaccine.
So far, all companies assessed have refused to take part in internationally coordinated initiatives designed to boost global supply by sharing knowledge and technology. They have also opposed proposals to temporarily lift intellectual property rights,
To coincide with the publication of the report, Amnesty International is launching a global campaign which calls for 2 billion vaccines to be delivered to low and lower-middle income countries before end of the year.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance